InvestSMART

PYC Therapeutics Limited (ASX: PYC) - Announcements

Current share price for PYC : $1.645 0.015 (0.92%)+

ASX company news and announcements for PYC Therapeutics Limited (PYC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PYC Therapeutics Limited (PYC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PYC Therapeutics Limited (PYC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PYC Therapeutics Limited (PYC)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$1,620 Completion of Small Shareholding Sale Facility 2 Aug 2024 3:05PM $0.095 $1.645 risen by 1,631.58%
$1,620 Extension of RP11 Single Dose Study Into Multiple Dose Study 23 Jul 2024 9:25AM $0.105 $1.645 risen by 1,466.67%
$1,620 Quarterly Activities/Appendix 4C Cash Flow Report 22 Jul 2024 9:22AM $0.110 $1.645 risen by 1,395.45%
$1,620 Initial Dosing Completed in Cohort 1 of RP11 MAD Study 17 Jul 2024 9:29AM $0.120 $1.645 risen by 1,270.83%
$1,620 Bioshares Biotech Summit Presentation 12 Jul 2024 9:33AM $0.125 $1.645 risen by 1,216%
$1,620 Commencement of RP11 Multiple Dose Trial 10 Jul 2024 9:06AM $0.120 $1.645 risen by 1,270.83%
$1,620 Notification regarding unquoted securities - PYC 2 Jul 2024 4:40PM n/a $1.645 n/a
$1,620 RP11 Drug Candidate Safe and Well Tolerated 1 Jul 2024 9:13AM $0.120 $1.645 risen by 1,270.83%
$1,620 PMS Drug Candidate Effective In Human Brain Cells 7 Jun 2024 8:44AM $0.100 $1.645 risen by 1,545%
$1,620 US FDA Grants Orphan Drug Designation to PYC Drug Candidate 24 May 2024 9:44AM $0.120 $1.645 risen by 1,270.83%
$1,620 Small Shareholdings Sale Facility 24 May 2024 8:22AM $0.120 $1.645 risen by 1,270.83%
$1,620 Issue of Options 23 May 2024 5:18PM $0.120 $1.645 risen by 1,270.83%
$1,620 Notification regarding unquoted securities - PYC 23 May 2024 5:15PM $0.120 $1.645 risen by 1,270.83%
$1,620 Change in substantial holding 17 May 2024 2:03PM $0.100 $1.645 risen by 1,545%
$1,620 Change of Director's Interest Notice 17 May 2024 2:02PM $0.100 $1.645 risen by 1,545%
$1,620 RP11 Clinical Trial Dosing Completed in Cohort 4 16 May 2024 9:12AM $0.105 $1.645 risen by 1,466.67%
$1,620 Successful GLP Tox Studies in Second Blinding Eye Disease 14 May 2024 9:08AM $0.095 $1.645 risen by 1,631.58%
$1,620 Q2 2024 Investor Webinar Presentation 9 May 2024 9:31AM $0.100 $1.645 risen by 1,545%
$1,620 Presentation of RP11 Clinical Trial Data at ARVO Conference 6 May 2024 8:56AM $0.105 $1.645 risen by 1,466.67%
$1,620 Ceasing to be a substantial holder 1 May 2024 4:48PM $0.097 $1.645 risen by 1,595.88%
$1,620 Q2 Investor Webinar 9 May 2024 1 May 2024 9:47AM $0.097 $1.645 risen by 1,595.88%
$1,620 Application for quotation of securities - PYC 30 Apr 2024 9:53AM $0.092 $1.645 risen by 1,688.04%
$1,620 RP11 Drug Candidate Progressing to Mid-Stage Human Trials 29 Apr 2024 9:29AM $0.092 $1.645 risen by 1,688.04%
$1,620 Quarterly Activities/Appendix 4C Cash Flow Report 26 Apr 2024 9:32AM $0.093 $1.645 risen by 1,668.82%
$1,620 Kidney Disease Drug Candidate Progressing to Human Trials 22 Apr 2024 9:02AM $0.091 $1.645 risen by 1,707.69%

201 - 225 of 961 results

Page 9 of 39

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.